Impact of CYP2D6 genotype and co-medication with paroxetine and clarithromycin on clomiphene metabolism in vivo

被引：0
|
作者：
Muerdter, T. [1 ,2 ]
Lehr, T. [3 ]
Igel, S. [1 ,2 ]
Kroener, P. [1 ,2 ]
Ganchev, B. [1 ,2 ]
Schaeffeler, E. [1 ,2 ]
Boehmer, G. [4 ]
Sonnenberg, M. [1 ,2 ]
Brauch, H. [1 ,2 ]
Kerb, R. [1 ,2 ]
Schwab, M. [1 ,2 ,4 ]
机构：
[1] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany
[2] Univ Tubingen, Stuttgart, Germany
[3] Univ Saarland, Klin Pharm, Saarbrucken, Germany
[4] Univ Klinikum Tubingen, Klin Pharmakol Abt, Tubingen, Germany
来源：
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY | 2016年 / 389卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
021
引用
收藏
页码：S8 / S8
页数：1
相关论文
共 50 条
  • [1] CYP2D6 GENOTYPE-DEPENDENT INTERACTION OF PAROXETINE AND CLARITHROMYCIN WITH THE INFERTILITY DRUG CLOMIPHENE
    Kerb, R.
    Ganchev, B.
    Boehmer, G. M.
    Igel, S.
    Sonnenberg, M.
    Schaeffeler, E.
    Schroth, W.
    Zanger, U.
    Brauch, H.
    Schwab, M.
    Muerdter, T. E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S59 - S59
  • [2] Impact of CYP2D6 Genotype on Paroxetine Serum Concentration
    Hole, Kristine
    Haslemo, Tore
    Molden, Espen
    THERAPEUTIC DRUG MONITORING, 2023, 45 (05) : 683 - 688
  • [3] Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia
    Yagihashi, Tatsuhiko
    Mizuno, Masafumi
    Chino, Bun
    Sato, Yuji
    Sakuma, Kei
    Takebayashi, Toru
    Takao, Takahashi
    Kosaki, Kenjiro
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2009, 24 (04) : 301 - 308
  • [4] CYP2D6 is primarily responsible for the metabolism of clomiphene
    Ghobadi, Cyrus
    Gregory, Anne
    Crewe, H. Kim
    Rostami-Hodjegan, Amin
    Lennard, Martin S.
    DRUG METABOLISM AND PHARMACOKINETICS, 2008, 23 (02) : 101 - 105
  • [5] Metabolism of antipsychotics and CYP2D6 genotype
    Schmider, J
    Walter, S
    Sachse, C
    Bauer, S
    Müller-Oerlinghausen, B
    Roots, I
    Brockmöller, J
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 358 (01) : R459 - R459
  • [6] EFFECT OF PAROXETINE ON THE PHARMACOKINETICS OF ATOMOXETINE IN DIFFERENT CYP2D6 GENOTYPE
    Kim, S. H.
    Byeon, J. Y.
    Kim, Y. H.
    Lee, H. J.
    Lee, Y.
    Lee, Y. J.
    Kim, D. H.
    Lim, H. J.
    Lee, S. Y.
    CLINICAL THERAPEUTICS, 2015, 37 (08) : E60 - E60
  • [7] Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol
    Patteet Lisbeth
    Haufroid Vincent
    Maudens Kristof
    Sabbe Bernard
    Morrens Manuel
    Neels Hugo
    European Journal of Clinical Pharmacology, 2016, 72 : 175 - 184
  • [8] Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol
    Lisbeth, Patteet
    Vincent, Haufroid
    Kristof, Maudens
    Bernard, Sabbe
    Manuel, Morrens
    Hugo, Neels
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 72 (02) : 175 - 184
  • [9] CYP2D6 genotype in psychiatric patients:: Impact on haloperidol metabolism.
    Schmider, J
    Sachse, C
    Walter, S
    Filler, D
    Kaiser, R
    Roots, I
    Brockmöller, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 185 - 185
  • [10] Erratum to: Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol
    Lisbeth Patteet
    Vincent Haufroid
    Kristof Maudens
    Bernard Sabbe
    Manuel Morrens
    Hugo Neels
    European Journal of Clinical Pharmacology, 2017, 73 : 127 - 127
12345